Tissue-Bonding Technology Improves Cancer Surgery

Clinical trials of 60 cancer patients in the Ukraine using a patented new biologic tissue-bonding technology have shown that the technology significantly reduces surgical times and reduces blood loss.

The tissue-bonding device bonds through radiofrequency fusion and reconnects living soft biologic tissue such as tissue or organs without the use of foreign matter or conventional wound closing devices such as sutures, staples sealant, and glue. The procedure leaves little or no visible scar after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing, or necrosis, the new technology bonds and reconnects incised tissue and avoids charring by using a low-heat delivery method aimed at restoring the normal functions of the organs and tissue.

"We realized a number of advantages, including reduction in surgery time up to 60%, significant reduction in blood loss and use of suture materials, reduction in hospital stay, elimination of suturing in treatment of uterine stumps, elimination of postoperative analgesics, reduction of the time needed to form anastomosis and formation of neat seams,” reported Prof. G.V. Bandor, M.D., director of the Donetsk Region Antineoplastic Center in the Ukraine.

Previously, 71 patients in the Ukraine were operated on for diseases of the lungs, mediastinum, pleura, and traumas of the chest, with good results. Surgeons at five Ukraine hospitals are now using the new technology in clinical trials, performing over 100 new surgeries each month for open and laparoscopic surgical procedures. The technology and exclusive worldwide rights to the medical device are owned by Consortium Management Group, Inc. (CSMG, Corpus Christi, TX, USA) through Live Tissue Connect, Inc., a subsidiary corporation.




Related Links:
Consortium Management Group, Inc.